Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
出版年份 2018 全文链接
标题
Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo
作者
关键词
Dacomitinib, Multidrug resistance, ATP-binding cassette transporters, ABCG2
出版物
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
Volume 37, Issue 1, Pages -
出版商
Springer Nature
发表日期
2018-02-20
DOI
10.1186/s13046-018-0690-x
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Dacomitinib versus gefitinib as first-line treatment for patients with EGFR -mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
- (2017) Yi-Long Wu et al. LANCET ONCOLOGY
- Phase 2 study of intermittent pulse dacomitinib in patients with advanced non-small cell lung cancers
- (2017) Helena A. Yu et al. LUNG CANCER
- ABCG2-overexpressing H460/MX20 cell xenografts in athymic nude mice maintained original biochemical and cytological characteristics
- (2017) Wei Zhang et al. Scientific Reports
- Dacomitinib, a pan-inhibitor of ErbB receptors, suppresses growth and invasive capacity of chemoresistant ovarian carcinoma cells
- (2017) Majid Momeny et al. Scientific Reports
- A Phase I Clinical Trial and Independent Patient-Derived Xenograft Study of Combined Targeted Treatment with Dacomitinib and Figitumumab in Advanced Solid Tumors
- (2016) Emiliano Calvo et al. CLINICAL CANCER RESEARCH
- ABCG2 inhibition as a therapeutic approach for overcoming multidrug resistance in cancer
- (2016) Maryam Hosseini Hasanabady et al. JOURNAL OF BIOSCIENCES
- A phase II trial of dacomitinib, an oral pan-human EGF receptor (HER) inhibitor, as first-line treatment in recurrent and/or metastatic squamous-cell carcinoma of the head and neck
- (2012) A. R. Abdul Razak et al. ANNALS OF ONCOLOGY
- Crizotinib (PF-02341066) reverses multidrug resistance in cancer cells by inhibiting the function of P-glycoprotein
- (2012) Wen-jing Zhou et al. BRITISH JOURNAL OF PHARMACOLOGY
- Loperamide, an FDA-Approved Antidiarrhea Drug, Effectively Reverses the Resistance of Multidrug Resistant MCF-7/MDR1 Human Breast Cancer Cells to Doxorubicin-Induced Cytotoxicity
- (2012) Yanfei Zhou et al. CANCER INVESTIGATION
- Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer
- (2012) Suresh S. Ramalingam et al. JOURNAL OF CLINICAL ONCOLOGY
- Apatinib (YN968D1) enhances the efficacy of conventional chemotherapeutical drugs in side population cells and ABCB1-overexpressing leukemia cells
- (2011) Xiu-zhen Tong et al. BIOCHEMICAL PHARMACOLOGY
- Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2
- (2009) Chun-ling Dai et al. CANCER LETTERS
- ABC Transporters as Potential Targets for Modulation of Drug Resistance
- (2009) L. Gatti et al. MINI-REVIEWS IN MEDICINAL CHEMISTRY
- Inhibition of P-glycoprotein (ABCB1)- and multidrug resistance-associated protein 1 (ABCC1)-mediated transport by the orally administered inhibitor, CBT-1®
- (2008) Robert W. Robey et al. BIOCHEMICAL PHARMACOLOGY
- Synthesis and structure–activity relationship studies on tryprostatin A, an inhibitor of breast cancer resistance protein
- (2008) Hiteshkumar D. Jain et al. BIOORGANIC & MEDICINAL CHEMISTRY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now